Poseida Therapeutics Hosts Gene Therapy R&D Day Highlighting New Scientific Advancements and Pipeline FocusPRNewsWire • 04/17/24
Poseida Therapeutics Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple MyelomaPRNewsWire • 04/08/24
Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)PRNewsWire • 04/01/24
Poseida Therapeutics to Present at H.C. Wainwright 2nd Annual Cell Therapy Virtual ConferencePRNewsWire • 03/19/24
Poseida: April 2024 Data Could Shed Light On Differentiated CAR-T AdvancementSeeking Alpha • 03/17/24
Poseida Therapeutics Announces FDA Orphan Drug Designation Granted to P-BCMA-ALLO1 for the Treatment of Multiple MyelomaPRNewsWire • 03/13/24
Poseida Therapeutics, Inc. (PSTX) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research • 03/08/24
Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2023PRNewsWire • 03/07/24
Poseida Therapeutics Highlights Recent Progress, Strategic Priorities and Anticipated 2024 Key MilestonesPRNewsWire • 01/04/24
Poseida Therapeutics: Non-Self CAR T Looks To Be Safe And Potentially ImpactfulSeeking Alpha • 12/21/23
Poseida Therapeutics Presents Positive Early Results from its Phase 1 Trial of Allogeneic CAR-T P-BCMA-ALLO1 in Relapsed-Refractory Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual MeetingPRNewsWire • 12/10/23
Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2023PRNewsWire • 11/09/23
Poseida Therapeutics, Inc. (PSTX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 11/02/23
All You Need to Know About Poseida Therapeutics, Inc. (PSTX) Rating Upgrade to BuyZacks Investment Research • 10/16/23
Biotechnology Breakthroughs: 3 Biotech Stocks That Could Make Early Investors RichInvestorPlace • 10/03/23
Poseida Therapeutics' Financial And Clinical Milestones Signal Upgrade To 'Strong Buy'Seeking Alpha • 09/27/23
Poseida Therapeutics Announces Strategic Investment by Astellas and Provides Business UpdatePRNewsWire • 08/07/23
Astellas and Poseida Therapeutics Announce Strategic Investment to Support Poseida's Commitment to Redefining Cancer Cell TherapyPRNewsWire • 08/07/23
Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-CD19CD20-ALLO1, an Allogeneic Dual CAR-T Cell Therapy for B-Cell MalignanciesPRNewsWire • 07/05/23